Bone Fragility in Diabetes and its Management: A Narrative Review.

Autor: Leungsuwan DS; Department of Endocrinology, Singapore General Hospital, Singapore, Singapore., Chandran M; Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, 20 College Road, ACADEMIA, Singapore, 169856, Singapore. mchandran7@gmail.com.; DUKE NUS Medical School, Singapore, Singapore. mchandran7@gmail.com.
Jazyk: angličtina
Zdroj: Drugs [Drugs] 2024 Sep; Vol. 84 (9), pp. 1111-1134. Date of Electronic Publication: 2024 Aug 05.
DOI: 10.1007/s40265-024-02078-5
Abstrakt: Bone fragility is a serious yet under-recognised complication of diabetes mellitus (DM) that is associated with significant morbidity and mortality. Multiple complex pathophysiological mechanisms mediating bone fragility amongst DM patients have been proposed and identified. Fracture risk in both type 1 diabetes (T1D) and type 2 diabetes (T2D) continues to be understated and underestimated by conventional risk assessment tools, posing an additional challenge to the identification of at-risk patients who may benefit from earlier intervention or preventive strategies. Over the years, an increasing body of evidence has demonstrated the efficacy of osteo-pharmacological agents in managing skeletal fragility in DM. This review seeks to elaborate on the risk of bone fragility in DM, the underlying pathogenesis and skeletal alterations, the approach to fracture risk assessment in DM, management strategies and therapeutic options.
(© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: